# Edoxaban

## Lixiana F.C. 30mg

| TAH Drug Code      | [**OLIX**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OLIX)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Deep vein thrombosis and pulmonary embolism: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant. Nonvalvular atrial fibrillation: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF)                                                                                                                                                                                                                                                                           |
| Dosing             | Prevent stroke and systemic embolism: oral 60mg once daily.  Treatment of DVT and PE: oral 60mg once daily after at least 5 days of parenteral anticoagulant therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Active pathological bleeding, hypersenstive.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | >10%: Hematologic and oncologic: Hemorrhage (22%) 1% to 10%: Dermatologic: Dermal hemorrhage (6%), skin rash (4%) Gastrointestinal: Gastrointestinal hemorrhage (4%), lower GI bleeding (3%) Genitourinary: Vaginal hemorrhage (9%), gross hematuria, urethral bleeding Hematologic and oncologic: Major hemorrhage, nonlife-threatening (7% to 9%; noncritical organ: 1%; critical organ: <1%), major hemorrhage (1%), oral hemorrhage (3%), anemia (2%), decreased hemoglobin (1%), puncture site bleeding (1%) Hepatic: Abnormal hepatic function tests (5% to 8%) Respiratory: Epistaxis (5%), pharyngeal bleeding |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

